Targeted Protein Degradation - Expanding the Druggable Proteome
- Asses PROTAC permeability, binary/ternary complex formation
- Determine target ubiquitination and proteasomal recruitment
- Monitor target protein degradation
Summary
This webinar will focus on a new generation of heterobifunctional small molecules, termed PROTACs, that hold significant therapeutic potential by inducing degradation of target proteins. Characterizing and optimizing PROTACs for degradation efficacy represents a significant challenge. Currently, the availability of live cell assays to interrogate the multiple steps required for PROTAC-mediated degradation is severely lacking. Here, we present a live-cell, NanoLuc® luciferase-based technology platform that enables characterization of PROTAC compound mechanism of action using either endpoint or real-time kinetic assay formats.
Speaker
Erik Bonke, PhD
Field Application Specialist
Promega GmbH
Erik Bonke received a Diploma in biology from the Johannes-Gutenberg University in Mainz, Germany in 2012. In his diploma thesis at the University Hospital in Mainz he worked at the genetic manipulation of murine embryonic stem cells in order to generate different transgenic mouse strains. He did his doctoral thesis at the University Hospital in Frankfurt am Main, where he focused on the mechanistic fundamentals of mitochondrial ROS generation and their physiological implication as cellular second messenger molecules, a process termed redox signaling. After completion of the experimental part of his thesis, Mr. Bonke joined Promega Germany to work as an Application Specialist with a main focus on cellular reporter technologies. As part of this position, he is giving frequent practical as well as theoretical workshops/seminars on the application of Promega's current luminescent reporter portfolio. In 2018, he was awarded a doctoral degree by the Johann Wolfgang Goethe University Frankfurt.